Healthcare / BiotechnologyNasdaqCM
$3.17
-0.06 (-1.71%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-21.0M · quality 69.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
21/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$30M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-87.0%
↓Gross Margin
N/A
•Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2012–2025 · 13 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
1.29x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-18.2M · FCF $-23.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||||
| Revenue | — | — | — | — | — | $23.0M | $135.1M | $19.9M | $13.5M | $911000.00 | $86000.00 | $3.8M | $3.2M | $12.0M | $1.2M |
| Net Income | $-18.2M | $-18.2M | $-29.4M | $-17.3M | $-20.5M | $-88.4M | $8.4M | $-106.4M | $-74.0M | $-58.1M | $-57.3M | $-24.7M | $-17.7M | $-4.0M | $-6.3M |
| EBITDA | $-26.7M | $-26.7M | $-28.0M | $-17.3M | $-20.5M | $-88.8M | $5.6M | $-111.5M | $-77.0M | $-59.0M | $-56.9M | $-24.3M | $-17.3M | $552000.00 | $-5.2M |
| EPS | -3.26 | -3.26 | -11.41 | -6.74 | -7.98 | -62.64 | 6.48 | -89.64 | -74.16 | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | -386.8% | 4.0% | -561.6% | -574.5% | -6529.6% | -67907.0% | -662.3% | -568.8% | -2.0% | -524.0% |
| Net Margin | — | — | — | — | — | -384.1% | 6.2% | -534.9% | -549.5% | -6380.4% | -66604.7% | -649.2% | -558.5% | -33.1% | -527.0% |
| Balance Sheet | |||||||||||||||
| Debt/Equity | 0.01 | 0.01 | -0.34 | -0.01 | -0.01 | — | — | — | — | — | — | — | — | — | — |
| Current Ratio | 2.25 | 2.25 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||||||
| Free Cash Flow | $-23.5M | $-23.5M | $-18.3M | $-21.0M | $-17.9M | $-60.1M | $-5.8M | $-109.2M | $-22.4M | $-54.9M | $-48.1M | — | — | — | — |
| Returns | |||||||||||||||
| ROE | -87.0% | -87.0% | 32.3% | 28.0% | 45.6% | -38.9% | 3.4% | -57.0% | -55.4% | -67.0% | -112.9% | -23.5% | -34.3% | 7.3% | 10.8% |
| Valuation | |||||||||||||||
| P/B | 1.18 | 1.18 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | |||||||||||||||
| Revenue Growth | — | — | — | — | — | -83.0% | 579.3% | 47.6% | 1378.5% | 959.3% | -97.7% | 19.7% | -73.4% | 905.4% | — |
| EPS Growth | 71.4% | 71.4% | -69.5% | 15.6% | — | -1066.7% | 107.2% | -20.9% | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-89.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-11.41 → -3.26
Residual
-89.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.